A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Inclusion Criteria:

• Has pathologically documented diagnosis of high-grade serous epithelial ovariancancer, primary peritoneal cancer, or fallopian tube cancer

• Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1

• Participants in Cohort A-1 Arm 1 and Arm 2: Has relapsed disease after 1 to 3 priorlines of therapy and radiographic evidence of disease progression ≥6 months (≥180days) after the last dose of platinum-based therapy (ie, platinum-sensitivedisease).

• Participants in Cohort B-1: Has relapsed disease after 1 to 3 prior lines of therapyand radiographic evidence of disease progression <6 months (<180 days) after thelast dose of platinum-based therapy (ie, platinum-resistant disease).

• Participants in Cohort B-1: Is a candidate for bevacizumab treatment

• Has provided tumor tissue from a core or excisional biopsy of a tumor lesion notpreviously irradiated

• Has an Eastern Cooperative Oncology Group performance status of 0 to 1 assessedwithin 7 days before allocation

• Human immunodeficiency virus (HIV)-infected participants must have well controlledHIV on anti-retroviral therapy

• Participants who are hepatitis B surface antigen positive are eligible if they havereceived hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and haveundetectable HBV viral load prior to allocation

• Participants with a history of hepatitis C virus (HCV) infection are eligible if HCVviral load is undetectable at screening

Exclusion Criteria:

• Has any of the following within 6 months before allocation: cerebrovascularaccident, transient ischemic attack, or other arterial thromboembolic event

• Has uncontrolled or significant cardiovascular disease

• Has clinically severe pulmonary compromise resulting from intercurrent pulmonaryillnesses including, but not limited to, any underlying pulmonary disorder, and anyautoimmune, connective tissue, or inflammatory disorders with potential pulmonaryinvolvement, or prior pneumonectomy

• Has ≥Grade 2 peripheral neuropathy

• Has received prior treatment with cadherin-6-targeted agents

• Has received prior systemic anticancer therapy including investigational agentswithin 4 weeks or 5 half-lives (whichever is shorter) before allocation

• Has received prior radiotherapy within 2 weeks of the start of study intervention,or has radiation-related toxicities, requiring corticosteroids

• Receives chronic steroid treatment

• Has known additional malignancy that is progressing or has required active treatmentwithin the past 3 years

• Has known active CNS metastases and/or carcinomatous meningitis

• Has history of (noninfectious) pneumonitis/interstitial lung disease (ILD) thatrequired steroids or has current pneumonitis/ILD

• Has active infection requiring systemic therapy

• HIV-infected participants with a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease